SCYNEXIS, Inc. (SCYX)
SCYXNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.50
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $34.84m
- P/E
- –
- EPS, last 4 quarters
- $-2.39
- Dividend yield
- –
- Day range
- –
- 52-week range
- $3.28 to $9.12
- Average volume
- 250.2k
- Previous close
- $3.50
Analysts
1 coveringBuy1 buy, 0 hold, 0 sell
Targets a year out average $32.00, +814.3% from here
Earnings
next estimate $-0.2400Next report
Dec 2025
-13.8%
Mar 2026
-320.0%
Jun 2026
+20.0%
Sep 2026
-77.5%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $335.0k | $18.65m | – | $235.0k |
| Gross profit | $335.0k | $18.65m | – | $235.0k |
| Operating income | -$8.40m | $10.52m | -$16.94m | -$7.78m |
| Net income | -$8.59m | $12.26m | -$21.30m | $7.40m |
News
8 latest- SCYNEXIS Secures Up To $214M In BARDA Support For SCY-247 Development; Stock Up RTTNews · Oct 22, 2026
- SCYNEXIS: IV SCY-247 Shows Favorable Safety And Exposure In Phase 1 Study RTTNews · Oct 22, 2026
- SCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug RTTNews · Oct 6, 2026
- Scynexis Names Sanjay Subramanian CFO RTTNews · Sep 10, 2026
- SCYNEXIS Swings To Q2 Profit; Expects Phase 1 Topline Data For SCY-770 In Q3 2026;Stock Up RTTNews · Aug 11, 2026
- SCYNEXIS (SCYX) Price Target Increased by 20.73% to 4.28Fintel · May 14, 2026
- SCYNEXIS Reports Wider Q1 Loss, Advances Pipeline Programs; Stock Down RTTNews · May 12, 2026
- Poxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up RTTNews · Mar 31, 2026
The company
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS's proprietary antifungal platform 'fungerps' includes BREXAFEMME (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development for the treatment and prevention of invasive fungal diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- scynexis.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.